24/7 Market News Snapshot 15 October, 2025 – Omeros Corporation (NASDAQ:OMER)
DENVER, Colo., 15 October, 2025 (www.247marketnews.com) – (NASDAQ:OMER) are discussed in this article.
Omeros Corporation (NASDAQ:OMER) has recently captured significant market attention as its shares surged by an impressive 103.71% in pre-market trading, reaching $8.352, up from the previous close of $4.100. This remarkable movement, accompanied by a trading volume of 5.35 million shares, reflects heightened investor enthusiasm and signals a potential bullish trend for the biotechnology firm.
In a transformative development for the company, Omeros has announced a major collaboration with Novo Nordisk, a leader in global healthcare innovation. This strategic partnership involves an asset purchase and license agreement that grants Novo Nordisk exclusive rights to develop and commercialize zaltenibart, which was previously known as OMS906. This investigational drug shows promise in treating rare blood and kidney disorders by inhibiting MASP-3, a key protein in the complement system involved in the immune response.
Omeros will benefit from an immediate upfront payment of $340 million, with the overall value of the agreement potentially exceeding $2.1 billion, dependent on reaching defined development and commercial milestones. Moreover, Omeros is set to receive tiered royalties based on zaltenibart’s net sales, enhancing its financial outlook.
“Partnering with Novo Nordisk, an industry leader, is a wonderful opportunity for us,” stated Gregory A. Demopulos, M.D., Chairman and CEO of Omeros. He emphasized that Novo Nordisk’s expertise and extensive reach will be vital in unlocking zaltenibart’s potential across various indications, particularly in paroxysmal nocturnal hemoglobinuria (PNH). Following the transaction’s expected completion in the fourth quarter of 2025, Novo Nordisk intends to initiate a global Phase 3 program for zaltenibart, with ambitions to expand its application to other rare conditions. This collaboration further solidifies both companies’ commitment to advancing innovative treatments for underserved patient populations while reinforcing Novo Nordisk’s leadership in the Rare Disease sector.